Charles Kirby, MD
Ophthalmology · Chattanooga, TNNPI 1740282755
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 28.4% of the total.
Across 128 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$727
- Alcon$395
- Amgen$363
- Aerie Pharmaceuticals, Inc.$270
- Sun Pharmaceutical Industries Inc.$134
- Bausch & Lomb, A Division Of Bausch Health US, LLC$128
- plus $538 from 12 others
Across 11 payments — averaging $55,612 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$569K
- AbbVie$42K
What the payments were for
- Food & beverage$2,53899%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $727 |
| Alcon | 15 | $395 |
| Amgen(2 entities) | 23 | $363 |
| Aerie Pharmaceuticals, Inc. | 11 | $270 |
| Sun Pharmaceutical Industries Inc. | 7 | $134 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $128 |
| Bausch & Lomb Americas Inc. | 7 | $125 |
| Novartis | 8 | $125 |
| Oyster Point Pharma, Inc. | 3 | $70 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| Ocular Therapeutix, Inc. | 2 | $30 |
| Genentech USA, Inc. | 1 | $28 |
| Kala Pharmaceuticals, Inc. | 2 | $28 |
| Harrow Eye, LLC | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Dompe US, Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,556 in reported general payments places this provider in the 60th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 259 | $121,052 |
| RestasisCyclosporine | 96 | $96,729 |
| RocklatanNetarsudil Mesylat/Latanoprost | 131 | $77,744 |
| XiidraLifitegrast | 31 | $31,128 |
| Cyclosporine | 44 | $25,381 |
| CombiganBrimonidine Tartrate/Timolol | 55 | $23,503 |
| Alphagan PBrimonidine Tartrate | 84 | $23,111 |
| Travoprost | 114 | $18,469 |
| Prednisolone Acetate | 231 | $10,703 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 32 | $8,332 |
| Ketorolac Tromethamine | 227 | $8,134 |
| Brimonidine Tartrate | 159 | $8,094 |
| Latanoprost | 586 | $7,280 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $5,857 |
| Ofloxacin | 193 | $3,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $727 | $264,394494 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $270 | $77,744131 claims |
| Bausch & Lomb Americas Inc.Xiidra | $125 | $31,12831 claims |
| AlconSimbrinza | $395 | $8,33232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Chattanooga
- John BierlyChattanooga$16K
- Michelle RobisonChattanooga$7K
- Deborah di StefanoChattanooga$6K
- Courtney RidnerChattanooga$6K
- Deborah ShermanNashville$3M
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian BiesmanNashville$630K
- Brian FowlerMemphis$206K
- Edward ChaumNashville$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.